Navigation Links
House funding bill will delay research progress and place new burdens on NIH
Date:7/24/2012

Bethesda, MD The fiscal year (FY) 2013 appropriations bill adopted by the House Labor, Health and Human Services, Education and Related Agencies (LHHS) Subcommittee on July 18th fails short of the needed investment in biomedical research at the National Institutes of Health (NIH) and will delay efforts to improve the well-being of our nation's citizens, reduce human suffering, and protect the nation against new and emerging health threats. "We are deeply concerned that the LHHS Subcommittee provided flat funding for NIH when the opportunities for major advances are unprecedented," stated FASEB President Judith S. Bond, PhD.

FASEB has been advocating for an appropriation of at least $32 billion for NIH as the baseline funding to sustain the research that capitalizes on the increasing scientific opportunities and the demonstrated capacity of the research enterprise. "The proposed funding level is substantially below that necessary to sustain the current research effort. Without adequate funding, NIH will have to sacrifice valuable lines of research and lose talented young scientists to keep up with rising costs and a continued loss of purchasing power" said Bond. Failing to continue the federal investment in NIH could endanger the U.S.'s position as a world leader in biomedical research.

FASEB is also concerned that policy language included in the LHHS bill could jeopardize NIH's ability to manage its portfolio effectively. For example, the bill prohibits NIH from spending funds on any research project until the director certifies that the project is of significantly high scientific value and will have a measureable impact on public health. "The NIH already has a peer review process that ensures that the research it supports is scientifically valuable," said Bond. "Therefore, it is neither necessary nor feasible for the Department of Health and Human Services to review the tens of thousands of activities funded annually by the agency." Moreover, this stipulation could have a deleterious impact on NIH's ability to fund the basic science that lays the foundation for the biomedical research enterprise. Much of the research that NIH supports is aimed at discovering what causes disease and how organisms function, yet the impact these studies would have on human health is not always immediately obvious.

The legislation also unwisely prescribes the number of training awards that NIH should fund in FY 2013. NIH is currently in the process of reviewing and determining how to implement the recommendations of its Advisory Committee to the Director Working Group on the Biomedical Research Workforce. "Mandating a certain number of awards could constrain the agency's ability to support the optimal number of research trainees," commented Bond.

FASEB looks forward to working with Congress, NIH, and the research community to sustain the nation's commitment to biomedical research and ensure that any policy changes do not constrain agency efforts to facilitate long-term progress in science and technology.


'/>"/>

Contact: Lawrence Green
lgreen@faseb.org
301-634-7335
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Housekeeping mechanism for brain stem cells discovered
2. Research!America says house funding levels for FY13 could undermine medical progress
3. Jim Demitrieus, CEO of EyeLock, Invited to White House Cyber Security Event
4. Weizmann Institute solar technology to convert greenhouse gas into fuel
5. NSF Leadership in Discovery and Innovation sparks White House US Ignite Initiative
6. Caution needed with new greenhouse gas emission standards
7. Carnegie Mellon Universitys Biometrics Center Selected To House New Pedo-Biometrics Research and Identity Automation Lab
8. Research!America says budget negotiations heighten urgency to protect research funding
9. Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship
10. University of Tennessee professor receives funding for clean coal research
11. European mountain plant population shows delayed response to climate change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... , March 24, 2017  Infectex Ltd., a ... today announced positive results of a Phase 2b-3 clinical ... regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 ... at Sequella, Inc. ( USA ) and ... A total of 140 patients were enrolled in a ...
(Date:3/24/2017)... March 24, 2017 Agenus Inc. (NASDAQ: AGEN), ... antibodies and cancer vaccines, today announced participation at the ...  Annual William Blair and Maidstone Life Sciences conference "Cancer ... in New York, NY . Agenus ... 29 at 9:40 am: Robert B. Stein , ...
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseq™ ... developed with input from industry experts to ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of the world,s ... systems, in terms of costs and resources. However, as the ... of innovative and efficient therapies that demonstrate higher chances of ... cancer treatments, a growing number of patients receiving immuno-oncology therapies ...
Breaking Biology Technology: